Colinz Laboratories Gears Up for Q3 Reveal on 24th January; Check Key Expectations Here

Click and Sign Up to Get Live Updates on Q3 Results 

Colinz Laboratories’ Q3 results FY26 are scheduled to be announced on 24th January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Colinz Laboratories Q3 Results 2026 Preview

• Colinz Laboratories’ revenue is expected to be in the range of ₹1.47 crore, a 21.29% YoY decrease. 
• Profit After Tax, or PAT, is projected to fall by 65.77% YoY. 
• Colinz Laboratories’ EBITDA is expected to rise to ₹0.03 crore. 
• Net profit is ₹0.05 crore, a fall 65.77% YoY 

Colinz Laboratories Share Performance 

• Over the past six months, Colinz Laboratories’ share price has fallen by 7.80% to ₹1.3546.20.
• Moreover, over the past year, the stock has decreased by 12.96%.
• Despite this weak short-term performance, Colinz Laboratories’ stock has delivered a financially sound 331.78% return over the past 5 years.
• As of 23rd January 2026, the stock traded at ₹46.20 per share.

Key Factors to Watch for Colinz Laboratories Q3 Results FY26 

• Revenue Trend: Whether net sales decline continues or stabilizes after recent contraction.
• Profitability & Margins: Movement in PAT and operating margins amid cost pressures and shrinking top line.
• Dependence on Other Income: Extent to which non-operating income supports profits, affecting quality of earnings.
• Cash Position & Liquidity: Any change in cash reserves and working capital given the small scale of operations.

Final Thoughts

Colinz Laboratories will announce its Q3 FY26 results on 23rd January 2026. Analysts expect 21.29% YoY revenue growth, a 65.77% fall in PAT, and a 77.97% fall in EBITDA. Colinz Laboratories focuses on manufacturing, marketing and exporting a wide range of pharmaceutical formulations — including allopathic, ayurvedic and nutraceutical products in tablets, capsules, injectables, creams, syrups and related dosage forms — for various therapeutic segments like gynecology, cardiology and gastroenterology.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

Top 10 Penny Stocks in India | Penny Stocks to Buy in 2026

Best Stocks to Buy Today: Explore Best Stocks With Expected Trends

Milky Mist Dairy Foods IPO Details: Everything You Should Know about 

Karbonsteel Engineering IPO GMP & Review: Should You Apply or Avoid?

Taurian MPS IPO GMP & Review: Should You Apply or Avoid?

Shringar House of Mangalsutra IPO GMP & Review: Apply or Avoid?

Dev Accelerator IPO GMP & Review: Apply or Avoid?

Vigor Plast India IPO Listing Preview: What to Expect Now?

Krupalu Metals IPO GMP: Day 3 IPO Live Updates